Panalgo and COTA collaborate to advance cancer care with real-world oncology data

Panalgo is partnering with COTA to integrate high-quality hematologic oncology data into its IHD platform, enhancing cancer research and accelerating real-world evidence (RWE) generation.

Panalgo, a Norstella company specializing in healthcare data analytics, has announced a strategic partnership with COTA, a provider of real-world data (RWD) focused on cancer care. Through this collaboration, COTA’s hematologic oncology data will be made available on Panalgo’s Instant Health Data Analytics (IHD) platform, further expanding the platform’s capabilities in RWE analytics.

COTA is known for its comprehensive and high-quality oncology data, sourced from electronic health records (EHRs) across both academic and community care settings in the US. The data offers valuable longitudinal insights into patient journeys, informing research on treatment patterns, real-world outcomes, and comparisons of care approaches. By integrating this data into Panalgo’s IHD platform, life sciences organizations can more easily access robust oncology data to enhance their analysis and decision-making processes.

Panalgo’s IHD platform is designed to enable rapid analytics without the need for complex programming. It is reported to be 85% faster than traditional custom programming, with a healthcare-specific data model and an extensive library of customizable algorithms. The platform also includes integrated machine learning capabilities and automated documentation, enabling users to answer research questions in real-time. These range from assessing treatment access and evaluating regulatory actions, to examining safety issues and generating evidence on the effectiveness and safety of treatments.

“We are delighted to join Panalgo’s data network as their first oncology partner specializing in hematologic cancers,” said COTA’s chief commercial officer, Sandy Leonard. “COTA’s longitudinal, high-quality oncology data enables researchers to generate meaningful insights that support decision-making across life science organizations. By leveraging Panalgo’s analytics platform, we can accelerate the speed and eliminate some of the operational barriers to generating these insights.”

The inclusion of COTA’s hematologic oncology data on the IHD platform expands the range of specialized oncology data accessible to life sciences organizations. Erik Maul, Senior Director of Partnerships at Panalgo, emphasized this, “COTA’s addition to Panalgo’s Partner Network offers life science organizations an innovative approach to access their specialized hematologic oncology RWD quickly through Panalgo’s IHD platform… By streamlining access to insights, we can accelerate RWE generation and improve healthcare outcomes.”